Executive Director, Norman Scherzer, and Real World Evidence Data Scientist, Dr. Yu Wang, of the Life Raft Group recently attended the ASCO (American Society of Clinical Oncologists) 2018 meeting in Chicago. Dr. Wang describes some of the studies most relevant to GIST. Clinical trials The phase Ib SURE trial from the Vall d’Hebron University Hospital […]
asco, Clinical Trials, GIST research
In May 2018, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), invited the Life Raft Group to the ISPOR 10th Patient Representatives Roundtable during the ISPOR 2018 conference in Baltimore, MD. Dr. Yu Wang, representing the LRG, joined representatives from 20 other patient advocacy groups along with representatives from academic research institutes, government agencies, […]
IMI Paradigm, ISPOR, Patient Experience Data, Research Matchmaking Project
Senior Director of Program Operations, Sara Rothschild, recently represented the Life Raft Group at the SPAEN (Sarcoma Patients EuroNet) meeting. Subsequent to the meeting, over 300 medical professionals gathered for the 7th annual ESMO (European Society for Medical Oncology) Sarcoma and GIST Conference. in Milan, Italy. Over 50 delegates gathered from Europe, US and India […]
ESMO, GIST research, Global, Sarcoma Research, SPAEN
On January 4th, 2018 Deciphera Pharmaceuticals, Inc, announced the start of the Phase 3 INVICTUS trial. This randomized trial is for 4th line GIST patients that have failed (or are intolerant) the three standard drugs for GIST, Gleevec, Sutent and Stivarga. The press release can be found here. Patients entering the trial will be randomized […]
DCC-2618, Deciphera Pharmaceuticals, Invictus Trial